upper
respiratori
tract
infect
uri
major
caus
morbid
among
vocal
art
profession
acut
impair
vocal
mechan
predispos
influenc
develop
seriou
vocal
sequela
review
present
salient
featur
current
avail
treatment
effect
influenza
viru
famili
respons
seriou
form
uri
present
includ
inactiv
vaccin
four
antivir
drug
approv
unit
state
mani
countri
prevent
treatment
influenza
live
attenu
vaccin
also
avail
vaccin
antivir
drug
develop
review
detail
current
option
avail
treat
influenza
noninfluenza
relat
uri
profession
voic
user
upper
respiratori
tract
infect
uri
nonspecif
term
use
describ
acut
infect
involv
nose
paranas
sinus
pharynx
larynx
trachea
bronchi
prototyp
ill
known
common
cold
patient
uri
develop
sore
throat
fever
hoars
make
would
inconveni
individu
potenti
crippl
vocal
art
perform
even
minor
urirel
symptom
lead
alter
voic
qualiti
vocal
fatigu
reduc
vocal
rang
moreov
laryng
inflamm
result
uri
predispos
singer
mucos
disrupt
hemorrhageresult
longterm
potenti
disastr
sequela
vocal
profession
virus
caus
uri
rhinoviru
parainfluenza
viru
coronaviru
adenoviru
respiratori
syncyti
viru
coxsackieviru
influenza
viru
account
case
adult
develop
averag
two
four
uri
per
year
occur
winter
month
compar
uri
caus
virus
influenza
system
ill
upper
respiratori
tract
one
multipl
organ
system
involv
recogn
distinct
caus
uri
given
seriou
natur
viral
uri
singer
thorough
understand
clinic
use
antivir
treatment
option
advis
voic
care
profession
antivir
treatment
categor
vaccin
prophylact
treatment
medic
influenza
rapidli
spread
around
world
season
epidem
impos
consider
econom
burden
form
health
care
cost
lost
product
pandem
dramat
present
influenza
major
genet
chang
viru
caus
three
influenza
pandem
centuri
kill
mani
million
peopl
name
come
old
medic
belief
unfavor
astrolog
influenc
caus
diseas
influenza
reach
peak
preval
winter
northern
southern
hemispher
winter
differ
time
year
actual
two
flu
season
year
hopesimpson
observ
influenza
outbreak
global
ubiquit
consist
occur
everi
month
follow
time
maximum
solar
radiat
area
therefor
world
health
organ
make
two
vaccin
formul
everi
year
one
northern
one
southern
hemispher
influenza
outbreak
northern
hemispher
tend
peak
januari
februari
exampl
influenza
pandem
reach
peak
virul
late
spring
summer
worldwid
octob
unit
state
remain
unclear
outbreak
influenza
occur
season
rather
uniformli
throughout
year
one
possibl
explan
peopl
indoor
often
winter
close
contact
often
enough
trigger
outbreak
anoth
cold
weaken
immun
system
howev
viru
contract
warm
indoor
environ
thrive
commerci
avail
specif
antivir
therapi
agent
limit
number
heretofor
aim
exclus
influenza
famili
virus
indic
side
effect
profil
well
understood
ionchannel
blocker
medic
class
agent
includ
amantadin
rimantadin
newer
class
agent
neuramidas
inhibitor
includ
zanamivir
oseltamivir
proven
effect
influenza
infect
although
current
approv
agent
treatment
noninfluenza
uri
one
promis
antirhinoviru
agent
pleconaril
close
receiv
us
govern
approv
sale
viral
entri
blocker
block
pocket
surfac
rhinoviru
control
uncoat
process
final
trademark
elderberri
extract
sambucol
razei
bar
jerusalem
israel
may
aid
shorten
durat
episod
influenza
contract
though
notabl
prevent
effect
influenza
b
two
type
influenza
virus
caus
epidem
human
diseas
influenza
virus
categor
subtyp
basi
two
surfac
antigen
hemagglutinin
neuraminidas
influenza
b
virus
categor
subtyp
sinc
influenza
influenza
influenza
b
virus
global
circul
influenza
virus
probabl
emerg
genet
reassort
human
virus
began
circul
wide
influenza
b
virus
separ
group
basi
antigen
characterist
new
influenza
viru
variant
result
frequent
antigen
chang
ie
antigen
drift
result
point
mutat
occur
viral
replic
influenza
b
virus
undergo
antigen
drift
less
rapidli
influenza
virus
amantadin
symmetrel
endo
pharmaceut
inc
chadd
ford
pa
rimantadin
flumadin
forest
pharmaceut
st
loui
mo
activ
type
influenza
viru
approv
prophylaxi
therapi
influenza
viru
infect
unit
state
begun
within
hour
onset
ill
treatment
amantadin
rimantidin
reduc
durat
system
respiratori
symptom
influenza
approxim
drug
shown
superior
antipyret
analges
regard
advers
reaction
report
frequent
recommend
dose
amantadin
nausea
dizzi
insomnia
less
frequent
report
advers
reaction
depress
anxieti
irrit
hallucin
confus
anorexia
dri
mouth
constip
ataxia
livedo
reticulari
peripher
edema
orthostat
hypotens
headach
somnol
nervous
dream
abnorm
agit
dri
nose
diarrhea
fatigu
advers
effect
disappear
promptli
upon
discontinu
drug
rimantidin
although
equal
effect
associ
less
frequent
central
nervou
system
cn
side
effect
amantadin
advers
event
report
frequent
recommend
dose
nausea
insomnia
dizzi
headach
nervous
adult
usual
dose
amantadin
rimantadin
mg
twice
daili
day
treatment
continu
hour
till
sign
symptom
disappear
sinc
drug
excret
via
kidney
dose
reduc
mgday
less
elderli
patient
renal
insuffici
tabl
prophylaxi
drug
must
administ
daili
throughout
period
highest
risk
influenza
infect
studi
shown
amantadin
rimantidin
effect
prophylaxi
influenza
use
medic
may
particularli
use
healthi
singer
perform
outbreak
region
infect
cast
member
especi
receiv
influenza
vaccin
previous
administ
vaccin
rel
ineffect
antigen
chang
circul
viru
outbreak
amantadin
use
simultan
inactiv
vaccin
fact
evid
protect
effect
amantadin
vaccin
addit
amantadin
may
also
use
situat
perform
known
contact
affect
individu
prophylaxi
amantadin
rimantidin
administ
promptli
sick
contact
must
continu
durat
local
outbreak
dosag
amantadin
rimantidin
mgday
adult
zanamivir
relenza
oseltamivir
tamiflu
member
new
class
drug
term
neuraminidas
inhibitor
activ
influenza
viru
type
type
b
agent
work
block
neuraminidas
enzym
surfac
influenza
viru
neuramidas
facilit
viru
spread
cell
cell
respiratori
tract
zanamivir
dri
powder
administ
inhal
twice
day
day
breathactiv
devic
oseltamivir
avail
pill
form
activ
strain
influenza
viru
minim
activ
b
strain
clinic
trial
shown
agent
need
start
within
hour
onset
symptom
impact
cours
diseas
oseltamivir
zanamivir
also
approv
prevent
influenza
pool
analysi
two
season
prophylaxi
studi
healthi
unvaccin
adult
adolesc
oseltamivir
mg
daili
taken
day
commun
outbreak
reduc
incid
laboratori
confirm
clinic
influenza
placebo
group
season
prevent
studi
elderli
resid
nurs
home
mg
oseltamivir
taken
day
day
reduc
incid
laboratori
confirm
clinic
influenza
placebo
group
oseltamivir
group
approxim
elderli
popul
vaccin
influenza
studi
postexposur
prevent
household
mg
oseltamivir
given
daili
within
day
onset
symptom
continu
day
result
studi
show
oseltamivir
reduc
incid
laboratori
confirm
clinic
influenza
placebo
group
oseltamivir
group
side
effect
oseltamivir
taken
prevent
similar
patient
took
drug
treatment
common
side
effect
nausea
vomit
headach
fatigu
efficaci
oseltamivir
prevent
influenza
establish
immunocompromis
patient
patient
continu
receiv
annual
influenza
vaccin
accord
guidelin
immun
practic
oseltamivir
substitut
influenza
vaccin
major
public
health
measur
prevent
influenza
use
inactiv
influenza
vaccin
influenza
strain
circul
previou
season
vaccin
viru
match
previou
year
circul
strain
well
immun
provid
protect
influenza
current
vaccin
formul
highli
purifi
associ
reaction
individu
experi
mild
fever
system
symptom
hour
inject
third
recipi
experi
tender
erythema
inject
site
live
attenu
influenza
vaccin
flumist
medimmun
vaccin
gaithersburg
md
also
develop
administ
intranas
stimul
local
antibodi
product
effici
convent
inactiv
vaccin
one
placebocontrol
studi
experiment
infect
adult
found
protect
efficaci
flumist
compar
inactiv
influenza
vaccin
vaccin
either
method
becom
effect
day
administr
live
attenu
vaccin
depend
replic
vaccin
recipi
nasopharynx
antivir
drug
influenza
start
week
receiv
vaccin
common
side
effect
includ
cough
runni
nosenas
congest
irrit
headach
chill
muscl
ach
fever
f
adult
nasal
congest
flumist
vs
placebo
rhiniti
flumist
vs
placebo
sinus
flumist
vs
placebo
report
significantli
often
flumist
recipi
compar
placebo
recipi
nasal
congest
runni
nose
sore
throat
headach
irrit
decreas
activ
muscl
ach
cough
common
advers
event
associ
vaccin
note
flumist
contraind
adolesc
receiv
aspirin
therapi
aspirincontain
therapi
associ
rey
syndrom
aspirin
wildtyp
influenza
infect
also
flumist
administ
individu
histori
asthma
reactiv
airway
diseas
intramuscularli
administ
inactiv
influenza
vaccin
avail
immun
highrisk
individu
present
summari
outlin
form
influenza
treatment
option
avail
profession
entrust
care
profession
voic
list
treatment
organ
accord
acuiti
need
intervent
prophylaxi
diseas
prevent
effect
strategi
profession
voic
user
take
form
either
chemoprevent
vaccin
shortterm
chemoprevent
indic
follow
condit
cours
prophylaxi
consid
interv
follow
immun
perform
influenza
activ
commun
perform
troup
time
immun
ii
cours
prophylaxi
consid
individu
perform
troup
known
contact
index
case
influenza
b
extend
cours
prophylaxi
cover
entir
period
signific
influenza
activ
commun
consid
select
set
protect
singer
vaccin
contraind
eg
singer
histori
anaphylact
reaction
egg
ii
protect
immun
highrisk
singer
vaccin
strain
poorli
match
circul
influenza
strain
chemoprophylaxi
accomplish
amantadin
rimantadin
zanamivir
oseltamivir
amantadin
mgday
oral
two
divid
dose
mgday
suscept
cn
side
effect
rimantadin
mgday
two
divid
dose
effect
influenza
oseltamivir
mgday
zanamivir
mg
inhal
daili
effect
influenza
b
medic
reduc
attack
rate
among
unvaccin
individu
begun
shortli
exposur
compar
trial
among
agent
done
c
vaccin
indic
perform
expect
work
citi
influenza
outbreak
inactiv
influenza
vaccin
concurr
administ
singer
expect
resid
influenza
affect
week
live
attenu
vaccin
howev
coadminist
chemoprophylaxi
regimen
sinc
limit
viral
replic
necessari
vaccin
modal
effect
healthi
peopl
influenza
cure
day
worst
symptom
usual
last
day
affect
singer
without
immin
import
perform
may
prefer
rest
light
voic
use
analges
cough
mixtur
may
use
home
treatment
eas
symptom
prevent
complic
usual
need
b
singer
perform
requir
antivir
medic
start
within
hour
onset
symptom
taken
reduc
sever
durat
symptom
caus
infect
influenza
b
viru
ii
shorten
length
ill
iii
control
outbreak
flu
perform
troup
iv
reduc
complic
flu
amantadin
rimantadin
dose
use
prophylaxi
appreci
decreas
durat
symptom
sign
rimantadin
prefer
patient
renal
failur
c
theoret
corticosteroid
potent
antiinflammatori
agent
could
thought
effect
reduc
nasal
symptom
result
clinic
studi
either
intranas
oral
steroid
shown
clinic
benefit
conclus
addit
seriou
health
threat
public
larg
influenza
present
potenti
sourc
signific
morbid
vocal
art
profession
review
highlight
number
intervent
current
dispos
charg
care
profession
voic
judici
use
prevent
therapeut
modal
combin
care
followup
optim
vocal
perform
importantli
prevent
seriou
injuri
vocal
mechan
futur
continu
improv
refin
capac
design
effect
vaccin
combin
new
structurebas
drug
design
techniqu
yield
increasingli
effect
intervent
voicepreserv
strategi
must
includ
time
vaccin
combin
educ
vocal
art
profession
recogn
earli
sign
symptom
influenza
allow
earliest
possibl
initi
antivir
therapi
